Nordic Lymphoma Group

The Nordic Lymphoma Group coordinates investigator-initiated lymphoma trials and registries across the Nordic countries, which share population registries that make long-term follow-up unusually complete. Its MCL2 and MCL3 trials established the Nordic regimen of intensified cytarabine-containing induction with rituximab and autologous transplant for younger patients with mantle cell lymphoma. NLG working groups cover aggressive, indolent, T-cell and Hodgkin lymphomas and collaborate with HOVON, the German groups, LYSA and IELSG. The group rotates its chair among the member countries.